In Guillain-Barré syndrome (GBS), both axonal and demyelinating variants can be mediated by complement-fixing anti–GM1 ganglioside autoantibodies that target peripheral nerve axonal and Schwann cell (SC) membranes, respectively. Critically, the extent of axonal degeneration in both variants dictates long-term outcome. The differing pathomechanisms underlying direct axonal injury and the secondary bystander axonal degeneration following SC injury are unresolved. To investigate this, we generated glycosyltransferase-disrupted transgenic mice that express GM1 ganglioside either exclusively in neurons [GalNAcT–/–-Tg(neuronal)] or glia [GalNAcT–/–-Tg(glial)], thereby allowing anti-GM1 antibodies to solely target GM1 in either axonal or SC membranes, respectively. Myelinated-axon integrity in distal motor nerves was studied in transgenic mice exposed to anti-GM1 antibody and complement in ex vivo and in vivo injury paradigms. Axonal targeting induced catastrophic acute axonal disruption, as expected. When mice with GM1 in SC membranes were targeted, acute disruption of perisynaptic glia and SC membranes at nodes of Ranvier (NoRs) occurred. Following glial injury, axonal disruption at NoRs also developed subacutely, progressing to secondary axonal degeneration. These models differentiate the distinctly different axonopathic pathways under axonal and glial membrane targeting conditions, and provide insights into primary and secondary axonal injury, currently a major unsolved area in GBS research.
Rhona McGonigal, Clare I. Campbell, Jennifer A. Barrie, Denggao Yao, Madeleine E. Cunningham, Colin L. Crawford, Simon Rinaldi, Edward G. Rowan, Hugh J. Willison
Title and authors | Publication | Year |
---|---|---|
Basic Pathological Mechanisms in Peripheral Nerve Diseases
Schenone A, Massucco S, Schenone C, Venturi CB, Nozza P, Prada V, Pomili T, Di Patrizi I, Capodivento G, Nobbio L, Grandis M |
International Journal of Molecular Sciences | 2025 |
P2X7 receptor antagonists modulate experimental autoimmune neuritis via regulation of NLRP3 inflammasome activation and Th17 and Th1 cell differentiation
Xie Y, Han R, Li Y, Li W, Zhang S, Wu Y, Zhao Y, Liu R, Wu J, Jiang W, Chen X |
Journal of Neuroinflammation | 2024 |
Guillain-Barré syndrome: a comprehensive review.
Bellanti R, Rinaldi S |
European Journal of Neurology | 2024 |
Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test
Pascual-Goñi E, Caballero-Ávila M, Querol L |
Neurology | 2024 |
Immune-Mediated Neuropathies: Pathophysiology and Management
Shastri A, Al Aiyan A, Kishore U, Farrugia ME |
International journal of molecular sciences | 2023 |
Neuromuscular disease: 2023 update
Margeta M |
Free neuropathology | 2023 |
Neuron-Schwann cell interactions in peripheral nervous system homeostasis, disease, and preclinical treatment
Oliveira JT, Yanick C, Wein N, Gomez Limia CE |
Frontiers in cellular neuroscience | 2023 |
Axolemmal nanoruptures arising from paranodal membrane injury induce secondary axon degeneration in murine Guillain‐Barré syndrome
Cunningham ME, McGonigal R, Barrie JA, Campbell CI, Yao D, Willison HJ |
Journal of the Peripheral Nervous System | 2023 |
Glial cells and neurologic autoimmune disorders
Li ZQ, Li TX, Tian M, Ren ZS, Yuan CY, Yang RK, Shi SJ, Li H, Kou ZZ |
Frontiers in cellular neuroscience | 2022 |
Case report: Recreational nitrous oxide abuse triggered peripheral neuropathy possibly through the immune-mediated pathogenesis
Dong MX, Wang Q, Xu JF, Hu L, Yu Y, Li T |
Frontiers in neurology | 2022 |
Development and In Vitro Differentiation of Schwann Cells
Hörner SJ, Couturier N, Gueiber DC, Hafner M, Rudolf R |
Cells | 2022 |
Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model
Campbell CI, McGonigal R, Barrie JA, Delaere J, Bracke L, Cunningham ME, Yao D, Delahaye T, Van de Walle I, Willison HJ |
2022 | |
Real time imaging of intra-axonal calcium flux in an explant mouse model of axonal Guillain-Barré syndrome
Cunningham ME, McGonigal R, Barrie JA, Yao D, Willison HJ |
Experimental Neurology | 2022 |
The endogenous calpain inhibitor calpastatin attenuates axon degeneration in murine Guillain‐Barré syndrome
McGonigal R, Cunningham ME, Smyth D, Chou M, Barrie JA, Wilkie A, Campbell C, Saatman KE, Lunn M, Willison HJ |
Journal of the Peripheral Nervous System | 2022 |